Cumberland Pharmaceuticals (NASDAQ: CPIX) — Perfil da empresa, notícias e dados financeiros
Cumberland Pharmaceuticals (NASDAQ:CPIX) is a specialty pharmaceutical company primarily engaged in the acquisition, development, and
Cumberland Pharmaceuticals
Cumberland Pharmaceuticals (NASDAQ:CPIX) is a specialty pharmaceutical company primarily engaged in the acquisition, development, and commercialization of prescription products. The company focuses on delivering innovative treatments for underserved patient populations in areas such as gastroenterology, oncology, and acute care medicine. With a diverse portfolio that includes both marketed products and products in various stages of clinical development, Cumberland Pharmaceuticals aims to improve patient care and outcomes through its high-quality medications and therapeutic solutions. The company's objectives center around expanding its product lineup through strategic partnerships, advancing its pipeline of potential new therapies, and continuing to grow its presence in the healthcare market.
Resumo
Operações
Produtos e/ou serviços de Cumberland Pharmaceuticals
- Acetadote - An intravenous formulation of acetylcysteine for the treatment of acetaminophen overdose.
- Caldolor - An injectable ibuprofen product designed to treat pain and fever in a hospital setting.
- Vaprisol - An intravenous treatment for euvolemic and hypervolemic hyponatremia.
- Vibativ - An antibiotic for certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.
- Omeclamox-Pak - A combination therapy for the treatment of Helicobacter pylori infection and duodenal ulcer disease.
- RediTrex - A line of prefilled methotrexate syringes designed for ease of use in the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, and severe psoriasis.
equipe executiva do Cumberland Pharmaceuticals
- A. J. KazimiFounder, Chairman, President & CEO
- John Michael HammVice President Accounting & Finance and CFO
- Todd M. AnthonyVice President of Organizational Development
- Adam S. MostafaManaging Director of Banking & Investor Relations
Últimas notícias sobre a Cumberland Pharmaceuticals
Histórico de dividendos
Dividendos por ação pagos pela Cumberland Pharmaceuticals, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $3.0000 |
Principais indicadores financeiros
Resultados divulgados pela Cumberland Pharmaceuticals, em USD.
- Cap. de mercado
- 73 mi
- Receita (TTM)
- 44,3 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.6
- Dividend yield
- 0.0%
- Margem de lucro
- -24.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 44,5 mi | -2,8 mi | -2,8 mi | |
| 37,9 mi | -6,4 mi | -6,5 mi | |
| 39,6 mi | -9,6 mi | -6,3 mi | |
| 42 mi | -5,7 mi | -5,6 mi |